PHARMACEUTICALS

Addresses

Assistance to Countries Seriously Affected by HIV/AIDS: Representative Sanders, E908-E910 [9MY]

Advertisements

Pharmaceutical Market Access Act (H.R. 2427): TREA Senior Citizens League, H9466 [15OC]

Amendments

Diseases: expand assistance to countries seriously affected by HIV/AIDS, malaria, and tuberculosis (H.R. 1298), S6445, S6449, S6476, S6478, S6481, S6484, S6486, S6531, S6532, S6562, S6563, S6564, S6565, S6566 [15MY], H3575, H3588, H3596, H3600, H3601, H3602, H3603, H3604, H3605, H3608, H3609, H3612 [1MY], H4375 [21MY]

FDA: provide authority to require certain research into drugs used in pediatric patients (S. 650), S9809, S9811, S9815 [23JY]

Federal Food, Drug, and Cosmetic Act: establish a program of fees relative to animal drugs (S. 313), S7165 [23MY], S7262 [3JN], S14279 [7NO]

Medicare: reform and provide prescription drug coverage (H.R. 1), S8898 [7JY], H5912, H5929, H5930, H5939 [25JN], H6121 [26JN]

———reform and provide prescription drug coverage (H.R. 1), consideration (H. Res. 299), H5963 [26JN]

———reform and provide prescription drug coverage (H.R. 1), consideration of conference report (H. Res. 463), H12245 [21NO]

———reform and provide prescription drug coverage (S. 1), S7932 [16JN], S8020, S8089, S8105, S8111, S8161, S8162 [18JN], S8173, S8174, S8182, S8184, S8203, S8246, S8247, S8248, S8249, S8252, S8253, S8255 [19JN], S8273, S8278, S8283, S8284, S8285, S8286, S8288, S8290, S8291, S8308, S8309, S8310, S8311, S8312, S8313, S8314 [20JN], S8325, S8330, S8331, S8335, S8336, S8337, S8340, S8341, S8345, S8348, S8350, S8351, S8353, S8367, S8368, S8369, S8370, S8371, S8372, S8374, S8375, S8376 [23JN], S8387, S8390, S8396, S8400, S8404, S8405, S8410, S8415, S8416, S8418, S8421, S8422, S8423, S8424, S8446, S8447, S8448, S8449, S8450, S8451, S8457, S8459, S8460, S8461, S8463, S8464, S8470, S8472, S8473, S8474, S8475, S8476 [24JN], S8480, S8483, S8487, S8489, S8495, S8496, S8500, S8502, S8512, S8515, S8516, S8521, S8522, S8536, S8538, S8539, S8578, S8579, S8580, S8581, S8582, S8583, S8584, S8585, S8586, S8587, S8588, S8589, S8590, S8592, S8593, S8594 [25JN], S8608, S8610, S8612, S8617, S8621, S8624, S8625, S8630, S8632, S8633, S8636, S8639, S8644, S8654, S8655, S8666, S8675, S8679, S8680, S8681, S8682, S8683, S8684, S8685, S8766, S8767, S8768, S8769, S8773, S8775, S8776, S8777, S8778, S8779, S8780, S8781, S8782, S8795, S8796 [26JN], S8898 [7JY]

Appointments

Conferees: H.R. 1, Medicare Prescription Drug and Modernization Act, H6681 [14JY]

———H.R. 1, Prescription Drug and Medicare Improvement Act, S8898 [7JY]

Articles and editorials

AARP Accused of Conflict of Interest, H12254 [21NO]

AARP Calls on Vermont Congressional Delegation To Vote for Medicare Rx Bill, S15694 [24NO]

AIDS Fuels Famine in Africa as Swaziland Farmers Die, Their Land Goes Unplanted, S9214 [10JY]

Drug Maker Pushed Painkiller Aggressively; Purdue PHARMA Has Marketed OxyContin Far Beyond Its Original Purpose, Newly Released Documents Show, E1246 [13JN]

Drug Plan a Placebo, H7234 [22JY]

Drugmakers Protect Their Turf—Medicare Bill Represents Success for Pharmaceutical Lobby, H12110 [21NO]

Flu Shots Save Lives, S5531 [30AP]

Health on the Border—Elderly Americans Head North and South To Find Drugs They Can Afford, H5347 [12JN]

Hobson's Medicare, S15536 [22NO], S15897 [25NO]

In Another Break With Past, Kenyans See Hope on AIDS, H4381 [21MY]

Long Lines Mar Canada's Low-Cost Health Care, H1693 [11MR]

Medco Accused of Favoring Merck Drugs, S8615 [26JN]

Medicare Bill Would Enrich Companies, S15724 [24NO]

Medicare Debate Turns to Pricing of Drug Benefits, S15735 [24NO]

Medicare Drug Folly, S7971 [17JN]

Medicare Reform—Try Again, S15909 [25NO]

Open Door to Drug Imports, H10540 [6NO]

Patients in Florida Lining Up for All That Medicare Covers, H9178 [2OC]

Prescription Drug Benefit Imminent, H6087 [26JN]

Some Successful Models Ignored as Congress Works on Drug Bill, S11074 [4SE]

Struggling Seniors, Medicare Drug Plan's Proof Is in the Purse, S8658 [26JN]

Time To Switch Drugstores?, S12367 [2OC]

U.S. Is Joining Lawsuit That Says Medco Put Profits Before Patients, S8614 [26JN]

U.S. Joining Suit Against Medco, S8614 [26JN]

When Half a Loaf Isn't Nearly Enough, S15606 [23NO]

Wrong Prescription—Congress Considers Inadequate Bills, S8659 [26JN]

Bills and resolutions

AARP: decision to support Medicare reform legislation (see H. Res. 461), H11702 [20NO]

Agriculture: prohibit open-air cultivation or use of human food or animal feed as host plant and establish tracking system to regulate genetically engineered pharmaceutical and industrial crops (see H.R. 2921), H7782 [25JY]

Armed Forces: prescription drug benefits for Medicare-eligible enrollees under defense health care plans (see H.R. 3390), H10129 [29OC]

Business and industry: eligibility of certain applicants for approval of a generic drug for a competition-free period (see H.R. 828), H702 [13FE]

———permit biomedical research corporations to engage in certain equity financings without incurring limitations on net operating loss carryforwards and certain built-in losses (see S. 1773), S13053 [22OC] (see H.R. 2968), H7784 [25JY]

———require prescription drug manufacturers, packers, and distributors to disclose certain gifts provided in connection with promotional or marketing activities (see S. 948), S5484 [29AP] (see H.R. 757), H698 [13FE]

Canada: permit commercial importation of prescription drugs from Canada (see H.R. 847), H703 [13FE] (see H.R. 2497), H5467 [17JN] (see H.R. 2769), H7085 [17JY]

Consumers: provide tax credit to retirement age individuals, remove barriers to importation, and prohibit certain regulation of Internet sites relative to prescription drugs (see H.R. 616), H321 [5FE]

Contraceptives: require equitable coverage of drugs, devices, and services under health insurance plans (see S. 1396), S9303 [11JY] (see H.R. 2727), H6867 [15JY]

Cuba: make exception to trade embargo for food, medicines, and goods and services intended for children, lift travel restrictions, and provide scholarships for certain Cuban nationals (see H.R. 3422), H10236 [30OC]

Dept. of HHS: give grant preference to States that require schools to allow students to self-administer medication for asthma or anaphylaxis (see H.R. 2023), H3761 [7MY]

———promulgate regulations for the reimportation of prescription drugs (see S. 1781), S13134 [23OC] (see H.R. 2427), H5266 [11JN]

———promulgate regulations for the reimportation of prescription drugs (H.R. 2427), consideration (see H. Res. 335), H7453 [23JY]

Dept. of Veterans Affairs: dispense medications for prescriptions written by private practitioners to veterans awaiting their first VA appointment for medical care (see S. 1112), S6978 [22MY] (see H.R. 2219), H4734 [22MY]

———dispense medications to veterans for prescriptions written by private practitioners (see H.R. 709), H391 [11FE] (see H.R. 998), H1462 [27FE] (see H.R. 2015), H3761 [7MY]

———dispense medications to veterans for prescriptions written by private practitioners and provide Medicare coverage to eligible veterans (see H.R. 1309), H1952 [18MR]

———dispense medications to veterans for prescriptions written by private practitioners when Dept. of Veterans Affairs physicians are unavailable (see H.R. 240), H134 [8JA]

———increase the quantity of supply of certain prescriptions furnished to veterans with chronic conditions (see H.R. 1921), H3635 [1MY]

———permit Medicare-eligible veterans to receive an outpatient medication benefit (see S. 1153), S7135 [23MY]

———pilot program to assess benefits of dispensing medications to veterans for prescriptions written by private practitioners (see H.R. 372), H170 [27JA]

———suspend authority to increase drug copayment for treatment of non-service-connected disabilities and increase pension rates for certain surviving spouses (see H.R. 627), H322 [5FE]

Diseases: address the international HIV/AIDS pandemic (see S. 250), S1812 [30JA]

———authorize appropriations for global initiative to combat polio (see H.R. 1892), H3570 [30AP]

———authorize assistance to combat HIV/AIDS pandemic in sub-Saharan Africa and the Caribbean (see H.R. 1857), H3451 [29AP]

———combat polio (see S. Res. 109), S4957 [8AP] (see S. Res. 266), S14804 [12NO] (see H. Res. 20), H60 [7JA]

———establish a comprehensive Federal effort relating to early detection of, treatments for, and prevention of cancer (see S. 1101), S6853 [21MY] (see H.R. 2741), H6868 [15JY]

———expand assistance to countries seriously affected by HIV/AIDS, malaria, and tuberculosis (see S. 1009), S5859 [7MY] (see H.R. 1298), H1908 [17MR]

———expand assistance to countries seriously affected by HIV/AIDS, malaria, and tuberculosis (H.R. 1298), consideration (see H. Res. 210), H3571 [30AP]

———expand assistance to countries seriously affected by HIV/AIDS, malaria, and tuberculosis (H.R. 1298), corrections in enrollment (see S. Con. Res. 46), S6707 [20MY]

———improve access to HIV/AIDS-related treatments and services in developing countries (see H.R. 2470), H5365 [12JN]

———improve data collection and dissemination between Federal and State registries to enhance the treatment and research of cancer (see S. 1899), S15287 [20NO]

———protect health of individuals receiving smallpox vaccine and provide compensation to and access to care for individuals sustaining injury as a result of smallpox vaccination (see H.R. 865), H704 [13FE]

———provide benefits for certain individuals sustaining injury as a result of smallpox vaccination (see H.R. 1413), H2310 [25MR] (see H.R. 1463), H2470 [27MR] (see H.R. 1770), H3351 [11AP]

———urge Group of Eight members to pledge and contribute a substantial amount to the fight against HIV/AIDS, tuberculosis, and malaria (see H. Con. Res. 180), H4130 [14MY]

Drugs: clarify definition of anabolic steroids, review sentencing guidelines for crimes involving steroids, and establish education programs relative to steroids (see S. 1780), S13134 [23OC]

———collect and assess scientific evidence regarding prescription drugs frequently used in federally funded health programs (see H.R. 2356), H5043 [5JN]

———correct impediments to allowing importation of prescription drugs into the U.S. by pharmacists and wholesalers for resale and by U.S. citizens for personal use (see H.R. 780), H700 [13FE]

———distribution chain of prescription drugs (see H.R. 2232), H4735 [22MY]

———eliminate safe-harbor exception for certain packaged pseudoephedrine products used in manufacturing methamphetamine (see S. 1784), S13134 [23OC]

———enhance competition for prescription drugs by increasing enforcement of existing antitrust laws relative to brand name and generic drugs (see S. 946), S5484 [29AP]

———establish an electronic system for practitioner monitoring of the dispensing of certain controlled substances (see H.R. 3015), H7949 [4SE]

———establish fairer pricing for prescription drugs for individuals without access to discounted prices (see H.R. 1694), H3051 [9AP]

———require that each prescription drug sold at retail bear a label that states full retail price of the drug (see H.R. 3677), H12919 [8DE]

Economic Growth and Tax Relief Reconciliation Act: freeze and repeal portions of the tax reduction and apply savings to a comprehensive Medicare outpatient prescription drug benefit (see H.R. 2514), H5551 [18JN]

FDA: establish restrictions relative to the qualifications of physicians prescribing the abortion drug known as RU-486 (see H.R. 486), H243 [29JA]

———establish therapeutic equivalence requirements for generic drugs (see H.R. 3401), H10129 [29OC]

———establish voluntary certification program for Internet and mail-order pharmacies and authorize, subject to conditions, importation of prescription drugs from Canada for personal use (see H.R. 2717), H6706 [14JY]

———provide authority to require certain research into drugs used in pediatric patients (see S. 650), S3881 [18MR] (see H.R. 2857), H7615 [24JY]

———withdraw approved application for the drug known as RU-486 and review process by which the FDA approved such drug (see S. 1930), S15407 [21NO] (see H.R. 3453), H10977 [6NO]

Federal Employees Health Benefits Program: ensure prescription drug coverage for Medicare-eligible enrollees is actuarially equal to benefit offered to general enrollees (see S. 1369), S8862 [27JN] (see H.R. 2631), H6262 [26JN]

Federal Food, Drug, and Cosmetic Act: amend relative to new animal drugs (see S. 741), S4512 [27MR] (see H.R. 2079), H4011 [13MY]

———establish a program of fees relative to animal drugs (see S. 313), S1977 [5FE] (see H.R. 1260), H1900 [13MR]

———establish recall authority for drugs and increase criminal penalties for sale or trade of prescription drugs knowingly adulterated or misbranded (see H.R. 3297), H9477 [15OC]

———establish requirements to allow sale of prescription drugs over the Internet (see H.R. 2652), H6263 [26JN]

———preserve effectiveness of medically important antibiotics used in treatment of human and animal diseases (see S. 1460), S9959 [25JY] (see H.R. 2932), H7782 [25JY]

———prohibit sale or trade of prescription drugs that were knowingly adulterated or misbranded (see H.R. 2936), H7783 [25JY]

———provide greater access to affordable pharmaceuticals (see S. 7), S34 (see S. 54), S36 [7JA] (see S. 1225), S7619 [10JN] (see H.R. 2491), H5467 [17JN] (see H.R. 2640), H6262 [26JN]

Foreign trade: impact of illegal importation of prescription drugs on regulatory protections afforded consumers (see H. Con. Res. 225), H5663 [19JN]

———permit importation of prescription drugs from Canada and Mexico (see H.R. 2629), H6262 [26JN]

GAO: conduct a study on price controls of foreign governments on pharmaceuticals (see H.R. 2577), H5813 [24JN]

Health: improve access to prescription drugs, prohibit tax deductions for direct-to-consumer prescription drug advertisements, and ban campaign contributions from pharmaceutical company chief executive officers (see H.R. 1733), H3301 [10AP]

———improve immunization rates by increasing the distribution of vaccines and improving and clarifying the vaccine injury compensation program (see S. 754), S4629 [1AP]

———improve patient safety and reduce incidence of medical errors (see S. 720), S4434 [26MR] (see H.R. 663), H389 [11FE]

———improve prescription drug benefits for veterans (see H.R. 2874), H7616 [24JY]

———permit an individual to be treated by a health care practitioner with any method of medical treatment such individual requests (see S. 1410), S9414 [15JY] (see H.R. 2085), H4129 [14MY]

———provide compensation for injuries resulting from smallpox countermeasures (see S. 719), S4434 [26MR]

———provide compensation for injuries resulting from smallpox countermeasures, provide protection against chemical or radiological agents, increase distribution of vaccines, and improve vaccine injury compensation (see S. 15), S3504 [11MR]

———reduce price of prescription drugs purchased by States for its employees, retirees, and pharmaceutical assistance beneficiaries (see H.R. 3662), H12918 [8DE]

———require notification by manufacturers before discontinuing production of a vaccine and develop a national vaccine stockpile (see S. 371), S2340 [12FE]

Health care professionals: implement an education loan repayment program for pharmacists (see S. 648), S3881 [18MR] (see H.R. 3591), H12307 [21NO]

Homeland Security Act: repeal certain provisions (see S. 41), S36 [7JA]

———repeal certain provisions relative to pediatric vaccine manufacturer liability (see S. 105), S37 [7JA] (see H.R. 248), H135 [8JA]

Insurance: coverage of prescription drugs (see H.R. 1243), H1811 [12MR]

———grant State high risk pool insurance programs reductions in prices charged for prescription drugs under Public Health Service Act prescription drug pricing agreements (see H.R. 1291), H1901 [13MR]

———prohibit a health plan from contracting with a pharmacy benefit manager (PBM) unless certain requirements are satisfied (see S. 1300), S8232 [19JN]

———provide access and choice for use of generic drugs under Federal health care programs (see S. 51), S36 [7JA]

———require comprehensive coverage for childhood immunizations (see H.R. 2095), H4130 [14MY]

Japan: urge honoring of commitments under the Market-Oriented Sector-Selective (MOSS) Agreement on Medical Equipment and Pharmaceuticals (see S. Con. Res. 80), S14335 [10NO] (see H. Con. Res. 324), H11149 [12NO]

Medicaid: allow States to enter into drug rebate agreements to make prescription drugs available to individuals who are not otherwise eligible for medical assistance (see S. 542), S3163 [5MR]

———clarify that inpatient drug prices charged to certain public hospitals are included in best price exemptions under the drug rebate program (see S. 1195), S7476 [5JN] (see H.R. 2409), H5173 [10JN]

Medicare: assure that enrollment in any prescription drug program is voluntary (see H.R. 635), H322 [5FE]

———coverage of certain drugs and biologicals under the prospective payment system for hospital outpatient services (see S. 1206), S7540 [9JN]

———coverage of certain self-administered intramuscular and subcutaneous drugs (see H.R. 1956), H3681 [6MY]

———coverage of drugs and biologicals (see H.R. 194), H58 [7JA] (see H.R. 1032), H1464 [27FE]

———coverage of home infusion drug therapies (see H.R. 2476), H5407 [16JN]

———coverage of immunosuppressive drugs for beneficiaries who receive an organ transplant (see S. 178), S1068 [16JA] (see H.R. 2223), H4734 [22MY]

———coverage of immunosuppressive drugs for beneficiaries who receive an organ transplant without regard to when the transplant was received (see H.R. 588), H320 [5FE]

———coverage of immunosuppressive drugs for kidney transplant patients (see S. 191), S1069 [16JA]

———coverage of oral anticancer drugs (see S. 1037), S5995 [9MY] (see H.R. 1288), H1901 [13MR]

———coverage of oral drugs to treat low blood calcium levels or elevated parathyroid hormone levels for patients with end stage renal disease (see H.R. 128), H56 [7JA]

———coverage of outpatient prescription drugs (see S. 7), S34 [7JA] (see H.R. 38), H53 [7JA] (see H.R. 1045), H1470 [3MR] (see H.R. 1568), H2702 [2AP] (see H.R. 2461), H5365 [12JN] (see H.R. 2498), H5467 [17JN] (see H.R. 3299), H9477 [15OC]

———deliver a meaningful benefit and lower prescription drug prices (see S. 1950), S15812 [24NO]

———eliminate privatization, improve prescription drug benefit, and repeal health savings accounts (see S. 1992), S16120 [9DE]

———establish a prescription drug discount card endorsement program (see H.R. 513), H268 [31JA]

———establish a safety net outpatient prescription drug program for certain indigent beneficiaries (see H.R. 3332), H9687 [17OC]

———establish voluntary outpatient prescription drug coverage program and modernize and reform payments and the regulatory structure (see H.R. 1199), H1744 [11MR]

———establish voluntary outpatient prescription drug discount and security program (see S. 778), S4823 [3AP] (see H.R. 2578), H5813 [24JN]

———expand coverage of certain self-injected biologicals (see S. 465), S2919 [27FE] (see H.R. 980), H1461 [27FE]

———permit the Dept. of HHS to enter into direct negotiations to promote the best prices for beneficiaries (see H.R. 3671), H12918 [8DE]

———provide beneficiaries with access to prescription drugs at Federal Supply Schedule prices (see H.R. 634), H322 [5FE]

———provide for negotiation of fair prices for prescription drugs (see S. 1994, 1999), S16120 [9DE] (see H.R. 3672), H12918 [8DE]

———provide prescription drug coverage and make improvements in payment for rural providers (see H.R. 2606), H5928 [25JN]

———reductions in prescription drug prices (see S. 891, 892), S5342 [11AP] (see H.R. 1400), H2269 [20MR]

———reductions in prescription drug prices for beneficiaries and women with breast cancer (see H.R. 896), H1332 [25FE]

———reform and provide prescription drug coverage (see S. 1), S7718 [11JN] (see H.R. 1), H5928 [25JN] (see H.R. 2473), H5407 [16JN]

———reform and provide prescription drug coverage (H.R. 1), consideration (see H. Res. 299), H5928 [25JN]

———reform and provide prescription drug coverage (H.R. 1), consideration of conference report (see H. Res. 463), H12306 [21NO]

———reform and provide prescription drug coverage (H.R. 1), consideration of conference report (H. Res. 463)—same-day consideration (see H. Res. 459), H11700 [20NO]

———reform payment method for covered drugs, drug administration services, and chemotherapy support services (see H.R. 1622), H2820 [3AP]

———reform reimbursement rates for chemotherapy drugs and administration (see S. 1303), S8300 [20JN]

———repeal Medicare Advantage Regional Plan Stabilization Fund (see S. 1995), S16120 [9DE]

———revise methodology by which payment for orphan drugs and biologicals is made under program prospective payment system for hospital outpatient department services (see H.R. 2700), H6602 [10JY]

Medicare Prescription Drug, Improvement, and Modernization Act: improve (see S. 1974), S15975 [25NO]

Members of Congress: provide that prescription drug coverage under a Federal health benefits plan not exceed the level of coverage under Medicare (see H.R. 2817), H7329 [22JY]

Mental health: protect children and their parents from being coerced into administering controlled substances in order to attend school (see S. 1390), S9244 [10JY] (see H.R. 2089), H4130 [14MY]

———protect children and their parents from being coerced into administering psychotropic medication in order to attend school (see H.R. 1170), H1743 [11MR]

National Organization for Rare Disorders: anniversary (see H. Con. Res. 147), H3304 [10AP]

National Vaccine Injury Compensation Program: amend (see H.R. 1349), H2131 [19MR]

———include hepatitis A vaccines (see S. 814), S4957 [8AP]

———include influenza vaccines (see S. 1817), S13909 [4NO]

———repeal certain amendments (see H.R. 237), H134 [8JA]

Orphan Drug Act: anniversary (see H. Con. Res. 147), H3304 [10AP]

Prices: provide for prices that are fair to the producer and the consumer (see H.R. 608), H321 [5FE]

Taxation: allow a deduction for amounts paid for health insurance and prescription drug costs of individuals (see H.R. 198), H58 [7JA]

———allow designation of income tax refunds for use in NIH biomedical research programs (see H.R. 1352), H2131 [19MR]

———allow drug manufacturers a tax credit if they certify that the price of a drug in the U.S. is not greater than its price in Canada or Mexico (see H.R. 354), H170 [27JA]

———allow Medicare beneficiaries a refundable credit for purchase of outpatient prescription drugs (see S. 142), S230 [13JA] (see S. 951), S5541 [30AP]

———apply excise tax to hepatitis A vaccines (see H.R. 1674), H2938 [8AP]

———disallow deductions and credits for companies who discriminate against Canadian pharmacies that pass along discounts to consumers living in the U.S. (see S. 477), S2920 [27FE]

———expand human clinical trials qualifying for the orphan drug credit (see H.R. 2931), H7782 [25JY]

———repeal the medicine and drugs limitation on the deduction for medical care (see H.R. 3596), H12307 [21NO]

———treatment of direct-to-consumer advertisements of prescription drugs (see H.R. 149), H57 [7JA]

———treatment of direct-to-consumer advertisements of prescription drugs that fail to provide certain information to the consumer (see H.R. 3155), H8490 [23SE]

Terrorism: provide incentives to commercial researchers to develop technologies and drugs to prevent and treat illnesses associated with a biological, chemical, or radiological weapons attack (see S. 666), S3993 [19MR]

Cloture motions

Medicare: reform and provide prescription drug coverage (H.R. 1), conference report, S15561 [22NO], S15698 [24NO]

Conference reports

Medicare Prescription Drug, Improvement, and Modernization Act (H.R. 1), H11877-H12103 [20NO]

Explanations

Changes in Conference Report on H.R. 1, Medicare Prescription Drug, Improvement, and Modernization Act, Relative to Payment System for Cancer Drugs, S15887 [25NO]

Factsheets

Animal Drug User Fee Act Performance Goals and Procedures: FDA Center for Veterinary Medicine, S14791 [12NO]

Letters

Allow Medicare beneficiaries enrolled in fallback plans to remain in such plans for two years by regulating contracting cycles: James Firman, National Council on the Aging, S8394 [24JN]

Animal Drug User Fee Act: Tommy G. Thompson, Sec. of HHS, S14791 [12NO]

Clarify status of Medicare as a secondary payor: William E. Moschella, Dept. of Justice, S8276 [20JN]

Employer-sponsored retiree prescription drug coverage plans: several labor unions, S8411 [24JN]

Enhance competition for prescription drugs by increasing enforcement of existing antitrust laws relative to brand name and generic drugs: Timothy J. Muris, FTC, S15886 [25NO]

Ensure Federal Employees Health Benefits Program prescription drug coverage for Medicare-eligible enrollees is actuarially equal to general enrollees: Charles L. Fallis, National Association of Retired Federal Employees, S8331 [23JN]

———Colleen M. Kelley, National Treasury Employees Union, S8331 [23JN]

Ensure that dual-eligible beneficiaries are eligible for Medicare prescription drug coverage: Paul Baldwin, Long Term Care Pharmacy Alliance, S8640 [26JN]

Expand assistance to countries seriously affected by HIV/AIDS, malaria, and tuberculosis: Jodi L. Jacobson, Center for Health and Gender Equity, S9555 [17JY]

———Joseph F. O'Neill, Dept. of State, S12772 [17OC]

———Joseph F. O'Neill, Office of National AIDS Policy, S9549 [17JY]

———Leonard S. Rubenstein, Physicians for Human Rights (organization), S9555 [17JY]

———Linda Bales, General Board of Church & Society of the United Methodist Church, S9555 [17JY]

———Maureen T. Shea and Jere Myrick Skipper, Episcopal Church, S9554 [17JY]

———Paul Zeitz, Global AIDS Alliance, S9554 [17JY]

FDA review of marketing and classification of the painkiller OxyContin for treatment of moderate pain: Representative Wolf, E2435, E2436 [23NO]

———Representative Wolf, Committee on Appropriations (House), E1245 [13JN], E2434 [23NO]

FDA withdrawal of approved application for the drug known as RU-486 and review approval process: Monty and Helen Patterson, S15474 [21NO]

Greater access to affordable pharmaceuticals: Business for Affordable Medicine (organization), H6121 [26JN]

Guarantee option of Medicare provided prescription drug coverage for all beneficiaries: Barbara B. Kennelly, National Committee To Preserve Social Security and Medicare, S8091 [18JN]

Improve access to HIV/AIDS-related treatments and services in developing countries: Joseph F. O'Neill, Executive Office of the President, S11223 [9SE]

Include certain Caribbean nations in expansion of assistance to countries seriously affected by HIV/AIDS, malaria, and tuberculosis: several ambassadors, S6483 [15MY]

Include educational information about prescription drugs in direct-to-consumer advertising: several health organizations, S8609 [26JN]

Increase awareness of autism spectrum disorder, support programs for research, and improve treatment: James W. Coll, H3536-H3538 [30AP]

International HIV/AIDS pandemic: Congressional Black Caucus, E409 [7MR]

Medicare alternative payment system for preferred provider organizations in highly competitive regions: Robert A. Sunshine, CBO, S8612 [26JN]

Medicare beneficiaries exemption from paying monthly premiums during any gap in coverage of their prescription drug benefit: Barbara B. Kennelly, National Committee To Preserve Social Security and Medicare, S8276 [20JN]

Medicare coverage of drug treatment therapy for HIV/AIDS patients: Tommy G. Thompson, Sec. of HHS, S15888 [25NO]

Medicare drug plans and organizations transfer of savings from drug manufacturers' rebate, discount, and incentive programs to local pharmacies and consumers: Barry F. Scher and John J. Fegan, Ahold USA, Inc., S8183 [19JN]

———John J. Motley III, Food Marketing Institute, S8183 [19JN]

———Joseph A. Piohler, Kroger Co., S8184 [19JN]

———Randy Hutton, Winn Dixie Stores, Inc., S8184 [19JN]

Medicare Prescription Drug, Improvement, and Modernization Act: Edward G. Rendell, Governor of Pennsylvania, H12252 [21NO]

———Gary Locke, Tom Vilsack and Bill Richardson, Democratic Governors' Association, S15636 [23NO]

———Jeb Bush, Governor of Florida, H12243 [21NO]

———John Yoo, S15752-S15755 [24NO]

———Republican Governors Association, H12243 [21NO]

———several Members of Congress, S15536 [22NO]

———several Representatives, H12109, H12184 [21NO]

———several Senators, S15536 [22NO], S15897 [25NO]

Medicare Prescription Drug and Modernization Act: Representative Thomas, Committee on Ways and Means (House), H6086 [26JN]

———Representative Tom Davis, Committee on Government Reform (House), H6086 [26JN]

———Richard McGraw, H6088 [26JN]

Medicare prescription drug benefit coverage gap: William D. Novelli, AARP, S8387 [24JN]

Medicare+Choice program: several Senators, S8526 [25JN]

National Vaccine Injury Compensation Program revisions: Melinda Clark, H2299 [25MR]

Permit commercial importation of prescription drugs from Canada: Thomas Huebner and M. Betrice Grause, Vermont Association of Hospitals and Health Systems, E2174 [30OC]

Pharmacy Education Aid Act: several pharmaceutical organizations and associations, S3896 [18MR]

Prescription Drug and Medicare Improvement Act: Gail E. Shearer, Consumers Union, S8615 [26JN]

———George E. Pataki, Governor of New York, S8271 [20JN], S8856 [27JN]

Prohibit a health plan from contracting with a pharmacy benefit manager (PBM) unless certain requirements are satisfied: Charles Bofferding, Society of Professional Engineering Employees in Aerospace, S8616 [26JN]

———Charles M. Loveless, American Federation of State, County and Municipal Employees, S8616 [26JN]

———Rod Shafer, Washington State Pharmacy Association, S8616 [26JN]

———Ronald F. Pollack, Families USA (organization), S8616 [26JN]

Religious organizations' campaign opposing drug reimportation reform legislation due to increased accessibility to abortion drug known as RU-486: Representatives Pitts and Chris Smith, H6997 [16JY]

———Tom Coburn, H6593 [10JY], H6997 [16JY]

Safety of vaccines containing mercury and thimerosal: Representative Burton, E1981 [7OC]

Smallpox Emergency Personnel Protection Act: Andrew L. Stern, Service Employees International Union, H2484 [31MR]

———Barry Kasinitz, International Association of Fire Fighters, H2483 [31MR]

———Charles M. Loveless, American Federation of State, County and Municipal Employees, H2484 [31MR]

———Charlotte Fraas, American Federation of Teachers, H2487 [31MR]

———Dennis Slocumb, International Union of Police Associations, H2487 [31MR]

———George C. Benjamin, American Public Health Association, H2487 [31MR]

———Rose Gonzalez, American Nurses Association, H2482 [31MR]

———W. Michael Scheld, Infectious Diseases Society of America, H2482 [31MR]

State grants for smallpox and other bioterrorism inoculation activities: Charles M. Loveless, American Federation of State, County and Municipal Employees, S4744 [3AP]

———Patrick M. Libbey, National Association of County & City Health Officials, S4744 [3AP]

———Rose Gonzalez, American Nurses Association, S4744 [3AP]

Vaccines containing thimerosal: Mark B. McClellan, FDA, H8259 [16SE]

Veterans Prescription Drug Benefits Act: Delatorro L. McNeal, Paralyzed Veterans of America (organization), E497 [18MR]

———Richard A. Jones, AMVETS (organization), E497 [18MR]

———Richard F. Weidman, Vietnam Veterans of America, Inc., E498 [18MR]

———Steve A. Robertson, American Legion, E497 [18MR]

———Thomas H. Miller, Blinded Veterans Association, E497 [18MR]

———William A. Wroolie, Military Order of the Purple Heart of the U.S.A., Inc., E497 [18MR]

Lists

Counterfeit prescription drugs, H7597 [24JY]

Organizations opposed to H.R. 1, Medicare Prescription Drug and Modernization Act, S15038 [18NO]

Pharmaceutical industry contributions to political parties, H6455 [9JY]

Senate and House staff members who contributed to H.R. 1, Medicare Prescription Drug, Improvement, and Modernization Act, S15914 [25NO]

Votes on point of order against Greater Access to Affordable Pharmaceuticals Act (2002), S15702 [24NO]

Motions

Dept. of HHS: promulgate regulations for the reimportation of prescription drugs (H.R. 2427), H7610 [24JY]

Diseases: expand assistance to countries seriously affected by HIV/AIDS, malaria, and tuberculosis (H.R. 1298), S6450, S6500 [15MY], H4375 [21MY]

Medicare: reform and provide prescription drug coverage (H.R. 1), H6181 [26JN], H6658 [14JY], H8063 [9SE], H8182 [10SE], H8257 [16SE], H8361 [17SE], H8467 [23SE], H8879, H8880 [24SE], H8925 [25SE], H8996 [30SE], H9062 [1OC], H9171, H9180 [2OC], H9252 [7OC], H9349 [8OC], H9708 [20OC], H9780 [21OC], H9967 [28OC], H10083 [29OC], H10314 [4NO], H10428, H10438 [5NO], H10528 [6NO], H11186 [17NO], H11395, H11493 [18NO], H11598 [19NO], H11845 [20NO]

———reform and provide prescription drug coverage (H.R. 1), conference report, S15698 [24NO], H12294 [21NO]

———reform and provide prescription drug coverage (H.R. 1), motion to instruct conferees, H10106 [29OC]

———reform and provide prescription drug coverage (S. 1), S8343 [23JN], S8402, S8403, S8404, S8409 [24JN], S8609, S8622, S8636 [26JN]

Press releases

AARP Endorses Medicare Prescription Drug Bill: AARP, H11498 [18NO]

Medicare Prescription Drug, Improvement, and Modernization Act (H.R. 1): Iowa Hospital Association, S15580 [22NO]

Vermont Physicians and Hospitals Strongly Support Passage of Medicare Reform Legislation: Vermont Medical Society, Vermont Association of Hospitals and Health Systems, and Fletcher Allen Health Care, Inc., S15694 [24NO]

Proposals

Treatment of biological products and generic drugs relative to patent challenges and exclusivity rules, S16106 [9DE]

Questions and answers

Access to HIV/AIDS drugs under H.R. 1, Medicare Prescription Drug, Improvement, and Modernization Act: Senator Feinstein and Tommy G. Thompson, Sec. of HHS, S15597 [23NO]

Remarks in House

AARP: alleged conflict of interest relative to endorsement of Medicare reform and prescription drug coverage, H11494-H11496, H11498 [18NO], H11520 [19NO], H12253 [21NO]

———decision to support Medicare reform legislation, H11635, H11638 [19NO]

Asthma Awareness Day: observance, H3647 [6MY]

Becton, Dickinson and Co.: tribute to efforts to combat the HIV/AIDS pandemic in Africa, E2404 [22NO]

Bush, President: evaluation of administration, H6873 [16JY]

Business and industry: require manufacturers to sell FDA-approved prescription drugs to U.S. wholesalers and retailers on the same terms as Canadian purchasers, H12752 [8DE]

Canada: permit commercial importation of prescription drugs from Canada, H6620, H6700 [14JY], E1489 [15JY], E2174 [30OC]

———permit commercial importation of prescription drugs from Canada (H.R. 847), H4768 [2JN]

Children and youth: importance of international children's health programs, E873 [6MY]

———improve safety and efficacy for children, H11570 [19NO]

Congress: accomplishments, H9690 [20OC]

———accomplishments of the 108th Congress, H6873 [16JY], H7229 [22JY]

Consumers: provide tax credit to retirement age individuals, remove barriers to importation, and prohibit certain regulation of Internet sites relative to prescription drugs (H.R. 616), E190 [12FE]

Courts: pediatric vaccine manufacturer liability protection, H1876 [13MR], H2299 [25MR], H2913, H2914 [8AP], H4220 [19MY]

Dept. of HHS: give grant preference to States that require schools to allow students to self-administer medication for asthma or anaphylaxis (H.R. 2023), H3647 [6MY]

———promulgate regulations for the reimportation of prescription drugs, H9354 [8OC], H9969 [28OC], H10539 [6NO], H11372-H11377, H11504, H11509-H11512 [18NO], H12106, H12111, H12178 [21NO], E2350 [20NO]

———promulgate regulations for the reimportation of prescription drugs (H.R. 2427), H5247 [11JN], H5453-H5459 [17JN], H6583, H6592-H6595 [10JY], H6682-H6685 [14JY], H6858-H6864 [15JY], H6873, H6996 [16JY], H7198, H7200, H7202 [21JY], H7457, H7458, H7459, H7595-H7611 [24JY], H7813 [3SE], H8261 [16SE], H9465 [15OC], E1617, E1621, E1622, E1642, E1647, E1648, E1658, E1659 [25JY]

———promulgate regulations for the reimportation of prescription drugs (H.R. 2427), consideration (H. Res. 335), H7531-H7541 [24JY]

———promulgate regulations for the reimportation of prescription drugs (H.R. 2427), motion to recommit, H7610 [24JY]

Dept. of Veterans Affairs: coverage of outpatient prescription drugs, H421 [12FE]

———dispense medications to veterans for prescriptions written by private practitioners (H.R. 2015), E888 [7MY]

———dispense medications to veterans for prescriptions written by private practitioners (H.R. 998), E322 [27FE]

———dispense medications to veterans for prescriptions written by private practitioners and provide Medicare coverage to eligible veterans (H.R. 1309), E496 [18MR]

———increase the quantity of supply of certain prescriptions furnished to veterans with chronic conditions (H.R. 1921), E1175 [9JN]

———negotiated prices for prescription drugs, H11499 [18NO]

Diseases: address the international HIV/AIDS pandemic, H446 [12FE], H1623-H1630 [5MR], E409 [7MR]

———authorize assistance to combat HIV/AIDS pandemic in sub-Saharan Africa and the Caribbean (H.R. 1857), E794 [29AP]

———encourage countries seriously affected by HIV/AIDS, malaria, and tuberculosis to accept U.S. food assistance, H3603 [1MY]

———expand assistance to countries seriously affected by HIV/AIDS, malaria, and tuberculosis, H330 [11FE], H6330 [8JY], H6437 [9JY], H7370-H7375, H7402 [23JY], H10364-H10367 [5NO], H12823 [8DE], E1460 [11JY], E2404 [22NO]

———expand assistance to countries seriously affected by HIV/AIDS, malaria, and tuberculosis (H.R. 1298), H2280 [25MR], H3457 [30AP], H3574, H3579-H3618 [1MY], H6583 [10JY], H7386 [23JY], E876 [6MY], E886 [7MY], E923 [9MY], E1057 [22MY], E1068, E1084 [23MY], E2258 [6NO]

———expand assistance to countries seriously affected by HIV/AIDS, malaria, and tuberculosis (H.R. 1298), Senate amendments, H4375-H4382 [21MY]

———expand assistance to countries seriously affected by HIV/AIDS, malaria, and tuberculosis (H.R. 1298), consideration (H. Res. 210), H3575-H3578 [1MY]

———expand assistance to countries seriously affected by HIV/AIDS, malaria, and tuberculosis (H.R. 1298), corrections in enrollment (S. Con. Res. 46), H4382 [21MY]

———expand assistance to countries seriously affected by HIV/AIDS, malaria, and tuberculosis (H.R. 1298), corrections in enrollment (S. Con. Res. 46), unanimous-consent agreement, H4511 [21MY]

———expand assistance to countries seriously affected by HIV/AIDS, malaria, and tuberculosis (H.R. 1298), unanimous-consent agreement, H4325 [20MY]

———expand assistance to countries seriously affected by HIV/AIDS through reductions in the Millennium Challenge Account, H7383-H7393 [23JY]

———funding preference to programs operating in developing countries emphasizing prevention of HIV mother-to-child transmission and lifelong care for children of HIV/AIDS infected individuals, H4378 [21MY]

———improve access to HIV/AIDS-related treatments and services in developing countries, H9200 [2OC], H9650 [17OC]

———include certain Caribbean nations in expansion of assistance to countries seriously affected by HIV/AIDS, H6821, H6822 [15JY]

———protect health of individuals receiving smallpox vaccine and provide compensation to and access to care for individuals sustaining injury as a result of smallpox vaccination (H.R. 865), E267, E268 [13FE]

———provide benefits for certain individuals sustaining injury as a result of smallpox vaccination (H.R. 1413), H2300 [25MR]

———provide benefits for certain individuals sustaining injury as a result of smallpox vaccination (H.R. 1463), H2476, H2478-H2494 [31MR], E638 [1AP], E677 [3AP]

———provide benefits for certain individuals sustaining injury as a result of smallpox vaccination (H.R. 1770), H3339, H3340 [11AP], E795 [29AP]

———provide benefits for certain individuals sustaining injury as a result of smallpox vaccination (H.R. 1770), corrections in engrossment, H3343 [11AP]

———reduce first year's funding for assistance to countries seriously affected by HIV/AIDS, malaria, and tuberculosis, H3605-H3607 [1MY]

———require a certain percentage of assistance to countries seriously affected by HIV/AIDS be expended for HIV/AIDS orphans and vulnerable children, H3604, H3605 [1MY], H7402 [23JY]

———strengthen accountability and reporting requirements relative to assistance to countries seriously affected by HIV/AIDS, malaria, and tuberculosis, H3597-H3600 [1MY]

———urge Group of Eight members to pledge and contribute a substantial amount to the fight against HIV/AIDS, tuberculosis, and malaria (H. Con. Res. 180), E959 [15MY]

Drugs: collect and assess scientific evidence regarding prescription drugs frequently used in federally funded health programs, H6560, H6561 [10JY]

———correct impediments to allowing importation of prescription drugs into the U.S. by pharmacists and wholesalers for resale and by U.S. citizens for personal use, H8002 [5SE]

———discrepancy in prescription drug prices between U.S. and foreign countries, H4095 [14MY], H4342-H4349 [20MY], H4845 [3JN], H4953 [4JN], H5056-H5058 [9JN], H5155-H5159 [10JN], H5346, H5360-H5362 [12JN], H5453-H5459 [17JN], H6434 [9JY], H6858-H6864 [15JY], H9257 [7OC]

———establish an electronic system for practitioner monitoring of the dispensing of certain controlled substances (H.R. 3015), E1823 [17SE]

———establish fairer pricing for prescription drugs for individuals without access to discounted prices (H.R. 1694), H5697, H5698 [23JN]

———investigate alleged pharmaceutical industry support of religious organizations' campaign opposing drug reimportation reform legislation due to increased accessibility to abortion drug known as RU-486, H6593 [10JY], H6682-H6685 [14JY], H6873, H6996 [16JY]

FDA: lobbying activities relative to Pharmaceutical Market Access Act, H7459 [24JY]

———provide authority to require certain research into drugs used in pediatric patients (S. 650), H11567-H11572 [19NO]

———provide greater access to affordable pharmaceuticals, H2313 [26MR]

———remove the abortion drug known as RU-486 from market and review approval process, H10459 [6NO]

———review marketing of the painkiller OxyContin and its classification for treatment of moderate pain, E1245 [13JN], E2434 [23NO]

Federal Employees Health Benefits Program: ensure prescription drug coverage for Medicare-eligible enrollees is actuarially equal to benefit offered to general enrollees (H.R. 2631), H6273, H6303-H6309 [8JY], E1411 [8JY], E1428, E1436 [9JY], E1446 [11JY]

Federal Food, Drug, and Cosmetic Act: amend relative to new animal drugs (H.R. 2079), E940 [13MY]

———establish a program of fees relative to animal drugs (H.R. 1260), H9054-H9059 [1OC], E462 [13MR]

———establish a program of fees relative to animal drugs (S. 313), H10293-H10297 [4NO]

———establish requirements to allow sale of prescription drugs over the Internet (H.R. 2652), E1617 [25JY]

Florence, AL: anniversary of Milner-Rushing Discount Drugs (business), E808 [30AP]

Foreign trade: permit importation of prescription drugs, H9709 [20OC]

———safety of imported prescription drugs, H5249 [11JN], H9253, H9254 [7OC], H9800 [21OC], H11599 [19NO]

Garcia, Jose: Robert Wood Johnson Foundation Community Health Leadership Award recipient, E1192 [10JN]

Global Fund To Fight AIDS, Tuberculosis, and Malaria (organization): funding, H3585 [1MY]

———initiate campaign to increase public awareness and encourage private contributions, H3601, H3602 [1MY]

———limit top salary levels of administrators to that of the Vice President of the U.S., H3602 [1MY]

Health: improve patient safety and reduce incidence of medical errors (H.R. 663), H1766-H1774 [12MR]

———national policy to provide health care and reform insurance procedures, H162 [27JA], H2208, H2210 [20MR], H8961, H9025 [30SE]

———safety of vaccines containing mercury and thimerosal, H9075 [1OC], E1981 [7OC]

———study link between child vaccinations and autism, H8258 [16SE], H9075 [1OC]

Health care professionals: implement an education loan repayment program for pharmacists (H.R. 3591), E2418 [22NO]

HIV Vaccine Awareness Day: observance, E970 [15MY]

Homeland Security Act: repeal certain provisions relative to pediatric vaccine manufacturer liability, H66, H119 [8JA], E89 [28JA], E113 [29JA], E164 [6FE]

House of Representatives: legislative priorities, H165 [27JA]

Insurance: grant State high risk pool insurance programs reductions in prices charged for prescription drugs under Public Health Service Act prescription drug pricing agreements (H.R. 1291), E453 [13MR]

———require comprehensive coverage for childhood immunizations (H.R. 2095), E948 [14MY]

Medicare: allow negotiated pricing for prescription drugs, H5912 [25JN]

———coverage of cancer drugs and treatments, E1800 [16SE]

———coverage of drugs and biologicals (H.R. 194), E11 [8JA]

———coverage of outpatient prescription drugs, H1477, H1501-H1507 [4MR], H1802 [12MR], H2694 [2AP], H3688 [7MY], H4790 [3JN], H5091, H5157 [10JN], H5246 [11JN]

———coverage of outpatient prescription drugs (H.R. 1568), E1416 [8JY]

———coverage of outpatient prescription drugs (H.R. 3299), E2041 [15OC]

———earnings test for beneficiaries relative to prescription drug coverage, H9181-H9187 [2OC], H9219 [7OC]

———eliminate gap in coverage of prescription drug benefit relative to cancer drugs, H5959 [26JN]

———establish voluntary outpatient prescription drug coverage program and modernize and reform payments and the regulatory structure (H.R. 1199), H5542 [18JN], E431, E433, E444 [12MR]

———privatization, H160 [27JA], H239 [29JA], H4759 [2JN], H5915-H5921 [25JN], H8182-H8189 [10SE], H9780-H9784 [21OC], H10439-H10443 [5NO], H11600, H11603, H11643 [19NO], H12903, H12905 [8DE], E2250 [6NO]

———prohibit implementation of premium support system which would require competition with private insurance carriers in delivering basic services, H10106-H10112 [29OC], H10528-H10534 [6NO]

———reductions in prescription drug prices, H5916-H5921 [25JN], H11857 [20NO]

———reductions in prescription drug prices (H.R. 1400), H5698, H5700 [23JN]

———reform, H187 [28JA], H1313-H1318 [25FE], H5179 [11JN]

———reform and provide prescription drug coverage, H10347 [5NO]

———reform and provide prescription drug coverage (H.R. 1), H5820, H5821, H5822, H5903-H5922 [25JN], H5942, H5943, H6007-H6104, H6107-H6256 [26JN], H6273, H6304-H6309 [8JY], H6438, H6448-H6455 [9JY], H6585 [10JY], H6658, H6685, H6700 [14JY], H7200 [21JY], H7234 [22JY], H7335 [23JY], H7792, H7812, H7813 [3SE], H8021 [9SE], H8262 [16SE], H9001 [30SE], H9219 [7OC], H9354 [8OC], H9488 [16OC], H9972 [28OC], H10159, H10160 [30OC], H10316, H10318 [4NO], H10347 [5NO], H11122 [7NO], H11191-H11199 [17NO], H11365, H11367, H11368, H11504, H11509-H11512 [18NO], H11518-H11520, H11629, H11634-H11647 [19NO], H11658, H11659, H11660, H11661, H11856-H11858, H11860, H11862, H11868-H11874 [20NO], E1411, E1415, E1416, E1419, E1422 [8JY], E1489, E1490 [15JY], E1642 [25JY], E1800 [16SE], E1956 [2OC]

———reform and provide prescription drug coverage (H.R. 1), conference report, H11362 [18NO], H12106, H12107, H12108-H12113, H12184, H12185, H12247-H12297 [21NO], H12750, H12752, H12761, H12846-H12854, H12879, H12883, H12901-H12908 [8DE], E2455 [25NO], E2474 [8DE]

———reform and provide prescription drug coverage (H.R. 1), conference report—unanimous-consent agreement, H12239 [21NO]

———reform and provide prescription drug coverage (H.R. 1), consideration (H. Res. 299), H5948, H5949, H5952-H5973 [26JN]

———reform and provide prescription drug coverage (H.R. 1), consideration of conference report (H. Res. 463), H12230-H12246 [21NO]

———reform and provide prescription drug coverage (H.R. 1), consideration of conference report (H. Res. 463)—same-day consideration (H. Res. 459), H12174-H12181 [21NO]

———reform and provide prescription drug coverage (H.R. 1), motion to instruct conferees, H6658-H6666 [14JY], H8182-H8189 [10SE], H8361-H8365 [17SE], H8879, H8880-H8887 [24SE], H8925-H8930 [25SE], H9062-H9067 [1OC], H9171-H9187 [2OC], H9349-H9354 [8OC], H9780-H9784 [21OC], H10106-H10112 [29OC], H10438-H10443 [5NO], H10528-H10534 [6NO], H11493-H11500 [18NO], H11598-H11605 [19NO], H11845-H11853 [20NO], E1907 [25SE], E1968 [2OC], E2013 [8OC], E2250 [6NO]

———reform and provide prescription drug coverage (H.R. 1), motion to recommit, H6254, H6255 [26JN]

———reform and provide prescription drug coverage (H.R. 2473), H5386-H5388, H5392-H5405 [16JN], H5415, H5417, H5446, H5449-H5451, H5453 [17JN], H5473, H5474, H5542-H5549 [18JN], H5553, H5555, H5639-H5642 [19JN], H5688, H5690-H5701 [23JN], H5717, H5718, H5719, H5720, H5796, H5799-H5808 [24JN], E1671 [3SE]

———reform payment method for covered drugs, drug administration services, and chemotherapy support services (H.R. 1622), H5802 [24JN]

———treatment of women, H5904, H5909, H5911 [25JN], H5954-H5956, H5959, H5961, H5962, H6109 [26JN]

Members of Congress: provide that prescription drug coverage under a Federal health benefits plan not exceed the level of coverage under Medicare, E1490 [15JY]

Mental health: protect children and their parents from being coerced into administering psychotropic medication in order to attend school, H3457 [30AP]

———protect children and their parents from being coerced into administering psychotropic medication in order to attend school (H.R. 1170), H1753 [12MR], H4382-H4387 [21MY], E432 [12MR]

National Organization for Rare Disorders: anniversary (H. Con. Res. 147), H4215-H4217 [19MY], E1000 [21MY]

National security: ensure that unapproved medical products made available during a declared emergency are returned to unapproved status following termination of declared emergency, H6928 [16JY]

National Vaccine Injury Compensation Program: repeal certain amendments (H.R. 237), H1779 [12MR], H1925 [18MR], H2100 [19MR], H2299 [25MR], H2913, H2914 [8AP], H3535 [30AP]

New Jersey: impact of Medicare legislation on Pharmaceutical Assistance to the Aged & Disabled (PAAD) program, H12262 [21NO]

NIH: biomedical research funding, H6517-H6521 [10JY]

Older Americans Act: funding, H6521 [10JY]

Orphan Drug Act: anniversary (H. Con. Res. 147), H4215 [19MY], E1000 [21MY]

Prescription drugs: reductions in prices, H2915 [8AP], H2942 [9AP], H3661 [6MY], H3834 [8MY], H3998 [13MY], H4095 [14MY], H4175 [15MY], H4763-H4770 [2JN], H4789 [3JN], H5039 [5JN], H5056-H5058 [9JN], H5155-H5159 [10JN], H5346, H5360-H5362 [12JN], H5446, H5447, H5453-H5459 [17JN], H5796, H5801 [24JN], H9253, H9254, H9257 [7OC], H9800 [21OC], H11196-H11198 [17NO], H12901-H12903, H12907 [8DE]

Slaven-Emond, AliceMarie: Robert Wood Johnson Foundation Community Health Leadership Award recipient, E1192 [10JN]

Taxation: allow a deduction for amounts paid for health insurance and prescription drug costs of individuals (H.R. 198), H1693 [11MR]

———allow drug manufacturers a tax credit if they certify that the price of a drug in the U.S. is not greater than its price in Canada or Mexico (H.R. 354), amendment process, H675 [13FE]

———treatment of direct-to-consumer advertisements of prescription drugs that fail to provide certain information to the consumer (H.R. 3155), E1862 [23SE]

United Steelworkers of America: support for health care bill of rights, E1688 [4SE]

Veterans: benefits funding, H10346 [5NO], E2257, E2261, E2263 [6NO]

———disability benefits, H10982, H10987, H10989, H11122 [7NO]

———health care funding, H4852 [3JN], H5179 [11JN], H5355 [12JN], H9471, H9473, H9475 [15OC], H9518 [16OC], H10322 [4NO], H10460 [6NO]

Women: ensure that programs in countries seriously affected by HIV/AIDS include a curriculum for men and boys that emphasizes gender equality and respect for women and girls, H3600 [1MY]

Wyeth (company): tribute to Wyeth Pharmaceuticals patient assistance program, E1350 [25JN]

Remarks in Senate

AARP: alleged conflict of interest relative to endorsement of Medicare reform and prescription drug coverage, S15585 [22NO], S15729 [24NO]

Biological weapons: State grants for smallpox and other bioterrorism inoculation activities, S4742-S4747 [3AP]

Business and industry: permit biomedical research corporations to engage in certain equity financings without incurring limitations on net operating loss carryforwards and certain built-in losses (S. 1773), S13055 [22OC]

———require manufacturers to sell FDA-approved prescription drugs to U.S. wholesalers and retailers on the same terms as Canadian purchasers, S8332-S8335, S8341-S8343 [23JN], S8403 [24JN]

Canada: permit commercial importation of prescription drugs from Canada, S8186, S8203-S8215 [19JN], S8265-S8269 [20JN]

Centers for Disease Control and Prevention: HIV/AIDS blood safety and injection safety in Africa plan funding, S11362-S11364 [10SE]

———improve injection safety in immunization programs in developing countries, S6614 [19MY]

———National Immunization Program funding, S11231, S11232 [9SE], S11272 [10SE]

———Vaccines for Children Program funding, S11335, S11336 [10SE]

Committee on Finance (Senate): tribute to staff for efforts relative to S. 1, Prescription Drug and Medicare Improvement Act, S8700 [26JN]

Contraceptives: require equitable coverage of drugs, devices, and services under health insurance plans, S3423-S3428, S3468-S3478 [11MR], S3613 [12MR]

———require equitable coverage of drugs, devices, and services under health insurance plans (S. 1396), S9416 [15JY]

Dept. of Agriculture: prohibit the purchase of chickens treated with fluoroquinolone for school nutrition programs, S14144 [6NO]

Dept. of HHS: develop literacy standards for informational materials to assist in the safe and appropriate use of prescription drugs, S8422 [24JN]

———drug addiction treatment programs funding, S4371 [25MR]

———include educational information about prescription drugs in direct-to-consumer advertising, S8609 [26JN]

———promulgate regulations for the reimportation of prescription drugs, S15531 [22NO]

———promulgate regulations for the reimportation of prescription drugs (S. 1781), S13142, S13184 [23OC], S13187, S13207, S13229 [24OC]

———require drug companies to test drugs against their competitors, disclose results of such tests in advertising, and include educational information about the drug in direct-to-consumer advertising, S8484, S8485 [25JN]

Dept. of Veterans Affairs: dispense medications for prescriptions written by private practitioners to veterans awaiting their first VA appointment for medical care (S. 1112), S6994 [22MY]

———permit Medicare-eligible veterans to receive an outpatient medication benefit (S. 1153), S7147-S7149 [23MY]

Diseases: address the international HIV/AIDS pandemic, S314 [15JA], S1793-S1797 [30JA], S1967 [5FE], S12715 [16OC]

———address the international HIV/AIDS pandemic (S. 250), S1814-S1816 [30JA]

———combat polio (S. Res. 109), S4974 [8AP]

———combat polio (S. Res. 266), S15303 [20NO]

———establish a comprehensive Federal effort relating to early detection of, treatments for, and prevention of cancer (S. 1101), S6864-S6867 [21MY]

———expand assistance to countries seriously affected by HIV/AIDS, S4409 [26MR]

———expand assistance to countries seriously affected by HIV/AIDS, malaria, and tuberculosis, S314 [15JA], S1347-S1350 [22JA], S1464 [23JA], S8871 [7JY], S9100 [9JY], S9182-S9184, S9186-S9188, S9190, S9191 [10JY], S12667, S12668 [16OC], S12772 [17OC], S13190-S13192 [24OC], S13256-S13258 [27OC], S13347-S13349, S13368, S13371, S13419 [28OC], S13638-S13647 [30OC], S16083, S16084 [9DE]

———expand assistance to countries seriously affected by HIV/AIDS, malaria, and tuberculosis (H.R. 1298), S5753 [6MY], S6036 [13MY], S6147, S6249 [14MY], S6415-S6421, S6445-S6450, S6475-S6500 [15MY], S6574, S6614 [19MY], S7119-S7121 [23MY]

———expand assistance to countries seriously affected by HIV/AIDS, malaria, and tuberculosis (H.R. 1298), corrections in enrollment (S. Con. Res. 46), S6786 [20MY], S6918 [22MY]

———expand assistance to countries seriously affected by HIV/AIDS, malaria, and tuberculosis (H.R. 1298), unanimous-consent agreement, S6196 [14MY]

———expand assistance to countries seriously affected by HIV/AIDS, malaria, and tuberculosis (S. 1009), S5878 [7MY], S6416, S6417 [15MY]

———expand assistance to countries seriously affected by HIV/AIDS, malaria, and tuberculosis through reductions in Dept. of Defense procurement, research, development, and evaluation funding, S9547-S9557 [17JY]

———expand assistance to countries seriously affected by HIV/AIDS, malaria, and tuberculosis through reductions in Millennium Challenge Account, S13645-S13648 [30OC]

———HIV/AIDS blood safety and injection safety in Africa plan funding, S13346, S13347 [28OC]

———improve access to HIV/AIDS-related treatments and services in developing countries, S10963-S10966 [2SE], S11021-S11023 [3SE], S11076 [4SE], S11215, S11218-S11223, S11225 [9SE], S11300-S11302 [10SE], S11410 [11SE], S11712-S11715 [18SE]

———improve data collection and dissemination between Federal and State registries to enhance the treatment and research of cancer (S. 1899), S15289 [20NO]

———include certain Caribbean nations in expansion of assistance to countries seriously affected by HIV/AIDS, malaria, and tuberculosis, S6482-S6484 [15MY]

———international mother-to-child HIV/AIDS transmission prevention activities funding, S11102, S11105 [4SE], S11330, S11331 [10SE]

———provide benefits for certain individuals sustaining injury as a result of smallpox vaccination (H.R. 1770), S5388-S5390 [11AP]

———require a certain percentage of assistance to countries seriously affected by HIV/AIDS be expended for HIV/AIDS orphans and vulnerable children, S6481, S6488 [15MY]

———require a certain percentage of assistance to countries seriously affected by HIV/AIDS be expended for women's health and empowerment programs and to reduce women's vulnerability to HIV/AIDS, S6485 [15MY]

———tuberculosis drug access funding, S13649 [30OC]

Drugs: AIDS Drug Assistance Program funding, S11228, S11229 [9SE], S11269 [10SE]

———clarify definition of anabolic steroids, review sentencing guidelines for crimes involving steroids, and establish education programs relative to steroids (S. 1780), S13139-S13142 [23OC]

———discrepancy in prescription drug prices between U.S. and foreign countries, S2793 [26FE]

———eliminate safe-harbor exception for certain packaged pseudoephedrine products used in manufacturing methamphetamine (S. 1784), S13146, S13147 [23OC]

———enhance competition for prescription drugs by increasing enforcement of existing antitrust laws relative to brand name and generic drugs, S8012 [18JN], S8351 [23JN], S8429, S8431 [24JN], S8692 [26JN], S15884-S15886 [25NO]

———enhance competition for prescription drugs by increasing enforcement of existing antitrust laws relative to brand name and generic drugs (S. 946), S5493, S5494 [29AP]

———ensure access to assured quality pharmaceuticals at the lowest possible price to countries seriously affected by HIV/AIDS, S6478-S6480 [15MY]

FDA: provide authority to require certain research into drugs used in pediatric patients (S. 650), S3897 [18MR], S9811-S9819 [23JY]

———withdraw approved application for the drug known as RU-486 and review process by which the FDA approved such drug (S. 1930), S15473 [21NO]

Federal Employees Health Benefits Program: ensure prescription drug coverage for Medicare-eligible enrollees is actuarially equal to benefit offered to general enrollees, S8330 [23JN]

Federal Food, Drug, and Cosmetic Act: amend relative to new animal drugs (S. 741), S4530 [27MR]

———establish a program of fees relative to animal drugs (S. 313), S7165 [23MY], S7266 [3JN], S14279-S14282 [7NO], S14791 [12NO]

———preserve effectiveness of medically important antibiotics used in treatment of human and animal diseases (S. 1460), S9968 [25JY]

———provide greater access to affordable pharmaceuticals, S1506 [28JA], S8187-S8198, S8200 [19JN], S8689-S8692 [26JN]

———provide greater access to affordable pharmaceuticals (S. 54), S58 [7JA], S7966 [17JN]

———provide greater access to affordable pharmaceuticals (S. 7), S134-S136 [9JA]

Global Fund To Fight AIDS, Tuberculosis, and Malaria (organization): funding, S6446-S6448, S6491, S6498 [15MY]

Health: efficacy of flu shots, S5531 [30AP]

———home health care funding, S11155 [5SE]

———national policy to provide health care and reform insurance procedures, S214 [13JA]

———permit an individual to be treated by a health care practitioner with any method of medical treatment such individual requests (S. 1410), S9422 [15JY]

———provide compensation for injuries resulting from smallpox countermeasures, provide protection against chemical or radiological agents, increase distribution of vaccines, and improve vaccine injury compensation (S. 15), S5791 [6MY], S6572 [19MY]

———recognize recent breakthroughs in medical research and support continued efforts in disease prevention and cures, S8839-S8842 [27JN]

———require notification by manufacturers before discontinuing production of a vaccine and develop a national vaccine stockpile (S. 371), S2356-S2358 [12FE]

———suspend the Outcome and Assessment Information Set requirement for non-Medicare and non-Medicaid patients to reduce paperwork, S8608 [26JN]

Health care professionals: implement an education loan repayment program for pharmacists (S. 648), S3896, S3897 [18MR], S8106 [18JN], S16054 [25NO]

Homeland Security Act: repeal certain provisions relative to pediatric vaccine manufacturer liability, S1439 [23JA]

———repeal certain provisions relative to pediatric vaccine manufacturer liability (S. 105), S81 [7JA]

———repeal certain provisions (S. 41), S45-S47 [7JA]

Institute of Medicine: findings of report entitled ``Hidden Costs, Value Lost—Uninsurance in America'', S8277 [20JN]

Insurance: economic impact of undiagnosed and untreated illnesses, S8277 [20JN]

———prohibit a health plan from contracting with a pharmacy benefit manager (PBM) unless certain requirements are satisfied, S8613-S8617 [26JN]

———prohibit a health plan from contracting with a pharmacy benefit manager (PBM) unless certain requirements are satisfied (S. 1300), S8244 [19JN]

Medicaid: allow States to enter into drug rebate agreements to make prescription drugs available to individuals who are not otherwise eligible for medical assistance (S. 542), S3112 [5MR]

———clarify that inpatient drug prices charged to certain public hospitals are included in best price exemptions under the drug rebate program (S. 1195), S7488 [5JN]

———reform, S1958-S1960 [5FE]

Medicare: allow beneficiaries enrolled in fallback plans to remain in such plans for two years by regulating contracting cycles, S8285 [20JN], S8390-S8394, S8408 [24JN]

———allow certain beneficiaries to purchase supplemental Medigap prescription drug plans, S8641, S8648 [26JN]

———allow certain States to opt out of prescription drug coverage program, S8687 [26JN]

———allow personal contributions to participate private fee-for-service plans, S8687 [26JN]

———clarification of a hospital ``under development'' relative to exemption from the self-referral limitation, S15743 [24NO]

———coordination of benefits for prescription drug plans and State pharmaceutical assistance programs, S8653 [26JN]

———coverage of cancer drugs and treatments, S11305 [10SE], S15739, S15740 [24NO]

———coverage of certain drugs and biologicals under the prospective payment system for hospital outpatient services (S. 1206), S7543 [9JN]

———coverage of drug treatment therapy for HIV/AIDS patients, S15596 [23NO], S15887, S15888 [25NO]

———coverage of FDA-approved prescription drug therapies for beneficiaries with multiple sclerosis, S8546 [25JN]

———coverage of immunosuppressive drugs for beneficiaries who receive an organ transplant (S. 178), S1071 [16JA]

———coverage of immunosuppressive drugs for kidney transplant patients (S. 191), S1082 [16JA]

———coverage of oral anticancer drugs (S. 1037), S6000, S6001 [9MY]

———coverage of outpatient prescription drugs, S1505, S1506 [28JA], S2047 [6FE], S2652 [25FE], S3050, S3052 [4MR], S3111 [5MR], S3974-S3979 [19MR], S4109, S4110 [20MR], S4265 [21MR], S4336 [25MR], S6214 [14MY], S6421, S6459, S6460 [15MY], S6641, S6642 [20MY], S7182-S7186 [2JN], S7270, S7272-S7274 [4JN]

———coverage of outpatient prescription drugs (S. 7), S134-S136 [9JA]

———coverage of syringes and medical supplies necessary for the administration of insulin, S8283 [20JN]

———definition of negotiated price for drug coverage relative to inclusion of dispensing fees, S15742, S15743 [24NO]

———eliminate gap in coverage of prescription drug benefit, S8387-S8389, S8392, S8393, S8403, S8404 [24JN]

———eliminate gap in coverage of prescription drug benefit relative to Alzheimer's disease drugs, S8624 [26JN]

———eliminate gap in coverage of prescription drug benefit relative to cancer drugs, S8481 [25JN], S8621, S8622 [26JN]

———eliminate privatization, improve prescription drug benefit, and repeal health savings accounts (S. 1992), S16127 [9DE]

———encourage availability of Medicare Advantage benefits in medically underserved areas, S8489-S8495 [25JN]

———ensure beneficiaries have convenient access to retail pharmacies for prescription drug coverage and prohibit the tying of contracts by health plans, S8487, S8488, S8489 [25JN], S15743 [24NO]

———ensure contributions for prescription drug coverage made by beneficiaries' former employers be treated as incurred costs, S8326, S8329 [23JN], S8394, S8410 [24JN]

———ensure that current retirees who are subject to lose prescription drug coverage will have the option of drug coverage under the Medicare fallback, S8660-S8662, S8701 [26JN]

———ensure that dual-eligible beneficiaries are eligible for prescription drug coverage, S8324-S8329 [23JN], S8393 [24JN], S8640, S8641, S8644, S8647 [26JN]

———establish permanent lifestyle modification program for beneficiaries, S8653 [26JN]

———establish voluntary outpatient prescription drug discount and security program, S8493 [25JN], S8663-S8675 [26JN]

———establish voluntary outpatient prescription drug discount and security program (S. 778), S4828 [3AP]

———evaluate alternative payment and delivery systems, S8539-S8545 [25JN], S8618-S8620, S8637, S8638 [26JN]

———exempt beneficiaries from paying monthly premiums during any gap in coverage of their prescription drug benefit, S8274-S8277 [20JN], S8486 [25JN]

———expand coverage of certain self-injected biologicals, S8346 [23JN], S8416-S8418 [24JN]

———expedite implementation of prescription drug coverage following enactment of reform legislation, S8349 [23JN], S8405-S8409 [24JN]

———guarantee option of Medicare provided prescription drug coverage for all beneficiaries, S8089-S8104, S8108 [18JN], S8657 [26JN]

———inclusion of disease management as a permanent part of the fee-for-service program, S8545 [25JN]

———income related increase in Medicare premium, S8680 [26JN]

———increase direct subsidy to employers retaining retiree prescription drug coverage plans, S8410-S8412 [24JN]

———increase the availability of discounted prescription drugs through grants to health centers, hospitals, and other qualifying institutions, to create in-house pharmacies, S8280 [20JN]

———limit premium increases, S8172-S8174, S8184-S8186, S8198-S8200 [19JN]

———limit the extent to which premiums and benefits of prescription drug coverage plans may vary, S8498-S8500 [25JN]

———lower premiums and improve coverage in prescription drug plans, S8625-S8632, S8637 [26JN]

———permit continuous open enrollment and disenrollment in prescription drug plans, S8401-S8403 [24JN]

———provide additional assistance to beneficiaries with certain serious medical conditions during any gap in coverage of their prescription drug benefit, S8630-S8632, S8636 [26JN]

———provide beneficiaries with information on advance directives, S8652 [26JN]

———provide cost-sharing prescription drug coverage for certain beneficiaries in certain income categories, S8412-S8414 [24JN]

———provide for equitable reimbursement rates for Medicare Advantage prescription drug plans, S8346 [23JN]

———provide for income-related increase in part B premium for individuals and married couples with incomes exceeding a certain level, S8677, S8678 [26JN]

———provide for negotiation of fair prices for prescription drugs (S. 1994), S16133 [9DE]

———provide for negotiation of fair prices for prescription drugs (S. 1999), S16138 [9DE]

———provide that beneficiaries who remain in the fee-for-service program receive the same drug benefit as those enrolled in a private plan, S4120 [20MR]

———reductions in prescription drug prices, S8490-S8493 [25JN]

———reform and provide prescription drug coverage, S12436-S12438 [3OC]

———reform and provide prescription drug coverage (H.R.. 1), S9581, S9582 [17JY]

———reform and provide prescription drug coverage (H.R. 1), S8898 [7JY], S9295-S9298 [11JY], S10960, S10962 [2SE], S11073 [4SE], S11146, S11155 [5SE], S11305 [10SE], S12151 [30SE], S14925-S14927 [17NO], S15036-S15038, S15047-S15051 [18NO], S15110, S15147-S15149, S15167-S15170, S15172-S15175 [19NO]

———reform and provide prescription drug coverage (H.R. 1), conference report, S15362-S15368, S15373-S15376, S15379-S15385, S15399 [21NO], S15514, S15519, S15521-S15569, S15574-S15588 [22NO], S15592-S15644, S15663-S15667 [23NO], S15670-S15771 [24NO], S15882-S15902, S15904-S15915, S15918, S15919, S15927-S15932, S15950 [25NO], S16104-S16107 [9DE]

———reform and provide prescription drug coverage (H.R. 1), conference report—unanimous-consent agreement, S15510 [21NO], S15528 [22NO]

———reform and provide prescription drug coverage (H.R. 1), insert S. 1 language in lieu, S8898 [7JY]

———reform and provide prescription drug coverage (S. 1), S7563, S7564, S7572 [10JN], S7665-S7668 [11JN], S7905-S7922 [16JN], S7943-S7974 [17JN], S8012, S8013-S8116 [18JN], S8167, S8202-S8216 [19JN], S8265-S8295 [20JN], S8323-S8354 [23JN], S8386-S8398, S8400-S8431 [24JN], S8479-S8546 [25JN], S8605-S8633, S8635-S8645, S8647-S8709 [26JN], S8832, S8850-S8856 [27JN], S8870, S8871 [7JY], S12910 [21OC], S12992 [22OC], S13068 [23OC], S14084 [6NO], S14960 [17NO]

———reform and provide prescription drug coverage (S. 1), unanimous-consent agreement, S7868 [13JN], S8706 [26JN]

———reform and provide prescription drug coverage (S. 1), unanimous-consent request, S8411 [24JN], S8686 [26JN]

———reform reimbursement rates for chemotherapy drugs and administration, S15887 [25NO]

———reform reimbursement rates for chemotherapy drugs and administration (S. 1303), S8302 [20JN]

———repeal Medicare Advantage Regional Plan Stabilization Fund (S. 1995), S16133 [9DE]

———require drug plans and organizations to transfer savings from drug manufacturers' rebate, discount, and incentive programs to local pharmacies and consumers, S8105-S8108 [18JN], S8183, S8184 [19JN]

———streamline regulations, S8350 [23JN]

Medicare Prescription Drug, Improvement, and Modernization Act: improve (S. 1974), S16022 [25NO]

Medicare/Medicaid: improve services, S1389-S1392, S1402, S1403 [23JA]

Members of Congress: provide that prescription drug coverage under a Federal health benefits plan not exceed the level of coverage under Medicare, S8350 [23JN], S8408 [24JN]

National Bipartisan Commission on Medicare Reform: establish, S8514 [25JN]

Patents: treatment of biological products and generic drugs relative to patent challenges and exclusivity rules, S16104-S16107 [9DE]

Small business: tribute to independent community pharmacies, S12367 [2OC]

South Africa: implementation of Government-sponsored HIV/AIDS treatment programs, S15272 [20NO]

Taxation: allow Medicare beneficiaries a refundable credit for purchase of outpatient prescription drugs (S. 951), S5597, S5598 [30AP]

———disallow deductions and credits for companies who discriminate against Canadian pharmacies that pass along discounts to consumers living in the U.S. (S. 477), S2935 [27FE]

———repeal dividend and top rate tax cuts and use savings for Medicare prescription drug program, S6437 [15MY]

Terrorism: provide incentives to commercial researchers to develop technologies and drugs to prevent and treat illnesses associated with a biological, chemical, or radiological weapons attack (S. 666), S4009-S4016 [19MR], S4152 [20MR]

Reports

Impact of Republican Medicare Proposals on Insurance Industry Revenues and Profits: Committee on Health, Education, Labor, and Pensions (Senate) Minority Staff, S15769 [24NO]

Reports filed

Animal Drug User Fee Act: Committee on Energy and Commerce (House) (H.R. 1260) (H. Rept. 108-287), H9032 [30SE]

———Committee on Health, Education, Labor, and Pensions (Senate) (S. 313) (S. Rept. 108-51), S6851 [21MY]

Biodefense Improvement and Treatment for America Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 15), S4375 [25MR]

Child Medication Safety Act: Committee on Education and the Workforce (House) (H.R. 1170) (H. Rept. 108-121), H4527 [21MY]

Consideration of Conference Report on H.R. 1, Medicare Prescription Drug, Improvement, and Modernization Act: Committee on Rules (House) (H. Res. 463) (H. Rept. 108-394), H12306 [21NO]

Consideration of H.R. 1, Medicare Prescription Drug and Modernization Act and H.R. 2596, Health Savings and Affordability Act: Committee on Rules (House) (H. Res. 299) (H. Rept. 108-181), H5928 [25JN]

Consideration of H.R. 1298, U.S. Leadership Against HIV/AIDS, Tuberculosis, and Malaria Act: Committee on Rules (House) (H. Res. 210) (H. Rept. 108-80), H3569 [30AP]

Consideration of H.R. 2427, Pharmaceutical Market Access Act: Committee on Rules (House) (H. Res. 335) (H. Rept. 108-231), H7453 [23JY]

Medicare Prescription Drug, Improvement, and Modernization Act: Committee of Conference (H.R. 1) (H. Rept. 108-391), H11700 [20NO]

Medicare Prescription Drug and Modernization Act: Committee on Energy and Commerce (House) (H.R. 2473) (H. Rept. 108-178), H5927 [25JN]

———Committee on Ways and Means (House) (H.R. 2473) (H. Rept. 108-178), H6867 [15JY]

Patient Safety and Quality Improvement Act: Committee on Energy and Commerce (House) (H.R. 663) (H. Rept. 108-28), H1678 [6MR]

———Committee on Health, Education, Labor, and Pensions (Senate) (S. 720) (S. Rept. 108-196), S14964 [17NO]

Pediatric Research Equity Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 650) (S. Rept. 108-84), S8722 [26JN]

Pharmacy Education Aid Act: Committee on Health, Education, Labor, and Pensions (Senate) (S. 648) (S. Rept. 108-189), S14176 [6NO]

Prescription Drug and Medicare Improvement Act: Committee on Finance (Senate) (S. 1), S7876 [13JN]

Same-Day Consideration of H. Res. 463, Consideration of Conference Report on H.R. 1, Medicare Prescription Drug, Improvement, and Modernization Act: Committee on Rules (House) (H. Res. 459) (H. Rept. 108-390), H11700 [20NO]

U.S. Leadership Against HIV/AIDS, Tuberculosis, and Malaria Act: Committee on International Relations (House) (H.R. 1298) (H. Rept. 108-60), H2863 [7AP]

Studies

Coordination of Care for Those With Multiple Chronic Conditions, S8620 [26JN]

Summaries

Biological, Chemical and Radiological Weapons Countermeasures Research Act (S. 666), S4016 [19MR]

Defense of Medicare and Real Medicare Prescription Drug Benefit Act (S. 1992), S16128 [9DE]

Prescription Drug and Medicare Improvement Act (S. 1): Specter Amendment on Advance Directives, S8653 [26JN]

———Specter Amendment on Coordination of Benefits for Prescription Drug Plans and State Pharmaceutical Assistance Programs, S8654 [26JN]

———Specter Amendment on Permanent Lifestyle Modification Program, S8653 [26JN]

———Specter Amendment on Physician Fee Schedule Payments, S8653 [26JN]

Tables

Depts. of Labor, HHS, and Education, and related agencies appropriations (H.R. 2660): HIV/AIDS funding, S11222 [9SE]

Global HIV/AIDS funding, S11222 [9SE]

HIV/AIDS, malaria, and tuberculosis initiatives funding, S9549 [17JY]

HIV/AIDS program funding levels, S11222 [9SE]

Immunization programs funding, S11232 [9SE]

Pharmaceutical company contributions by party (2002), H5912 [25JN]

Projected U.S. spending for global HIV/AIDS initiatives (2004-2008), S9549 [17JY]

U.S., Canadian negotiated Dept. of Veterans Affairs and Dept. of Defense prescription drug prices, H5912 [25JN]

Vaccines containing thimerosal, H8259 [16SE]

Testimonies

Global Fund To Fight AIDS, Tuberculosis, and Malaria (organization) Funding: Elton John, S6498 [15MY]

———Senator Sessions, S6498 [15MY]

Prescription Drug and Medicare Improvement Act: Committee on Finance (Senate), S8661 [26JN]

Texts of

H. Con. Res. 147, anniversary of Orphan Drug Act and National Organization for Rare Disorders, H4215 [19MY]

H. Res. 210, consideration of H.R. 1298, U.S. Leadership Against HIV/AIDS, Tuberculosis, and Malaria Act, H3575 [1MY]

H. Res. 299, consideration of H.R. 1, Medicare Prescription Drug and Modernization Act and H.R. 2596, Health Savings and Affordability Act, H5952 [26JN]

H. Res. 335, consideration of H.R. 2427, Pharmaceutical Market Access Act, H7531 [24JY]

H. Res. 459, same-day consideration of H. Res. 463, consideration of conference report on H.R. 1, Medicare Prescription Drug, Improvement, and Modernization Act, H12174 [21NO]

H. Res. 463, consideration of conference report on H.R. 1, Medicare Prescription Drug, Improvement, and Modernization Act, H12230 [21NO]

H.R. 1, Medicare Prescription Drug and Modernization Act, H6007-H6077 [26JN]

H.R. 1, Prescription Drug and Medicare Improvement Act, S8898-S8997 [7JY]

H.R. 663, Patient Safety and Quality Improvement Act, H1766-H1771 [12MR]

H.R. 1170, Child Medication Safety Act, H4382 [21MY]

H.R. 1260, Animal Drug User Fee Act, H9054-H9057 [1OC]

H.R. 1298, U.S. Leadership Against HIV/AIDS, Tuberculosis, and Malaria Act, H3588-H3596 [1MY]

H.R. 1463, Smallpox Emergency Personnel Protection Act, H2478-H2480 [31MR]

H.R. 1770, Smallpox Emergency Personnel Protection Act, H3340-H3343 [11AP]

H.R. 2427, Pharmaceutical Market Access Act, H7595 [24JY]

H.R. 2631, ensure prescription drug coverage for Federal Employees Health Benefits Program Medicare-eligible enrollees is actuarially equal to benefit offered to general enrollees, H6303 [8JY]

S. 1, Prescription Drug and Medicare Improvement Act, S7720 [11JN]

S. 41, repeal certain Homeland Security Act provisions, S47 [7JA]

S. 54, Greater Access to Affordable Pharmaceuticals Act, S55-S58 [7JA]

S. 105, repeal certain Homeland Security Act provisions relative to pediatric vaccine manufacturer liability, S81 [7JA]

S. 178, Comprehensive Immunosuppressive Drug Coverage for Transplant Patients Act, S1071 [16JA]

S. 313, Animal Drug User Fee Act, S7168-S7171 [23MY], S14279-S14282 [7NO], H10293-H10296 [4NO]

S. 371, require notification by manufacturers before discontinuing production of a vaccine and develop a national vaccine stockpile, S2357 [12FE]

S. 648, Pharmacy Education Aid Act, S16054-S16057 [25NO]

S. 650, Pediatric Research Equity Act, S3898-S3900 [18MR], S9811-S9813, S9816-S9818 [23JY], H11567-H11569 [19NO]

S. 778, Medicare Rx Drug Discount and Security Act, S4828-S4834 [3AP]

S. 948, Drug Company Gift Disclosure Act, S5494 [29AP]

S. 1112, Veterans' Prescription Drug Reform Act, S6994 [22MY]

S. 1153, Veterans Prescription Drugs Assistance Act, S7148 [23MY]

S. 1780, Anabolic Steroid Control Act, S13141 [23OC]

S. 1784, Methamphetamine Blister Pack Loophole Elimination Act, S13147 [23OC]

S. 1974, Medicare Preservation and Drug Price Fairness Act, S16022 [25NO]

S. 1994, Efficiency in Government Health Care Spending Act, S16133 [9DE]

S. 1995, repeal Medicare Advantage Regional Plan Stabilization Fund, S16133 [9DE]

S. Con. Res. 46, corrections in enrollment of H.R. 1298, U.S. Leadership Against HIV/AIDS, Tuberculosis, and Malaria Act, S6717, S6786 [20MY], S6918 [22MY], H4382 [21MY]

S. Con. Res. 80, urge Japan to honor commitments under the Market-Oriented Sector-Selective (MOSS) Agreement on Medical Equipment and Pharmaceuticals, S14364 [10NO]

S. Res. 109, combat polio, S4974 [8AP]

S. Res. 266, combat polio, S14817 [12NO], S15303 [20NO]